drugset / Trial / NCT01513733
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon which to improve upon. Thus, the primary objective of this study is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).
Timeline
- Start
- 2012-01
- Primary completion
- 2015-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tasquinimod | Small molecule | 0.25 mg | — |
| Subject | Tasquinimod | Small molecule | 0.5 mg | — |
| Subject | Tasquinimod | Small molecule | 1 mg | — |